Senior Consultant, Infectious Diseases, Fortis Memorial Research Institute, Gurgaon
Part 5 of 9 in Tuberculosis & HIV - An Insight
Post-Exposure Prophylaxis: Acting Within 72 Hours of a Possible HIV Exposure
September 6, 2026
A resident drawing blood from an HIV-positive patient, six years into treatment and admitted with PCP pneumonia, gets accidentally pricked with the needle. The panic that follows is as much social as medical, and the clinical answer has to be immediate: post-exposure prophylaxis (PEP) cannot wait for test results, because HIV testing itself has a window it cannot see through.
Blood Carries the Highest Risk, Not Sex
Sexual intercourse is the most common route of HIV transmission, but it is not the highest-risk one. Blood and blood product exposure carries the greatest transmission risk of all recognised routes, ahead of perinatal transmission and sexual intercourse. The fluids to treat as high-risk are blood, semen, vaginal secretions, breast milk, cerebrospinal fluid and other body fluids; sharing razors or blades with someone whose viral load is high is a real, avoidable route of blood-borne transmission that is easy to overlook.
Start Within 72 Hours, Never Wait for a Test
PEP should start as soon as possible after exposure, and the defined efficacy window closes at 72 hours; in rare circumstances it has been given up to the fifth day, but efficacy beyond 72 hours is no longer well established. Because HIV testing has a window period of two to four weeks before a new infection reliably shows up, an HIV test taken on the day of exposure only reflects exposures from weeks earlier, never the one that just happened. Waiting for a baseline result before starting PEP defeats the purpose: the decision to start should be based on the exposure itself and the source patient's status, not a same-day test.
The Regimen and the Follow-Up
PEP uses the same three-drug backbone as standard antiretroviral therapy: an NRTI backbone (TDF or TAF) plus emtricitabine plus an integrase inhibitor, most commonly dolutegravir, combined as a single pill and continued for 28 days from the point of exposure. Antibody testing follows 28 days after the exposure to confirm the outcome.
This guide is based on a live Jivo Masterclass: Dr. Neha Rastogi Panda taught doctors across Africa on March 30, 2025.
FROM THE LIVE Q&A
Dr. Emanuela
What are the early signs of HIV?
Dr. Neha Rastogi Panda
The early signs, known as acute HIV syndrome, look like a flu. Most patients who are symptomatic present with intermittent fever for two to three months, fatigue or weakness, weight loss, loss of appetite, cough, cold, sore throat, more frequent minor illnesses than usual, and loose motions or diarrhoea. This symptom complex over the first month or two is what we call acute HIV syndrome.
Book a Consultation with Dr. Neha Rastogi Panda
Book on WhatsAppOr message us on WhatsApp: +91 98182 98669
Frequently Asked Questions
Why don't we use the urine LAM test and stool test for all patients?▼
The urine lipoarabinomannan (LAM) test is reserved for tuberculosis diagnosis, and it has only been validated for patients with a CD4 count below 100. Below that threshold, a high tuberculosis bacterial burden allows the antigen to wash out into the urine; above it, the test loses sensitivity and specificity, so extrapolating it to every patient isn't supported. On stool testing for other opportunistic infections, a high viral load before treatment changes the normal gut flora, so a stool sample will often show excess normal flora and candida, which makes interpreting it for treatment decisions difficult specifically in HIV patients.
Are there any antiretrovirals that can have prolonged action for up to three or six months?▼
Yes. Cabotegravir, a longer-acting integrase inhibitor, combined with rilpivirine from the non-nucleoside reverse transcriptase inhibitor family, was studied in the TANGO trial and showed viral suppression sustained for close to three months from a single dose. Their half-life runs to about 24 to 26 weeks, so the combination is given as one intramuscular or subcutaneous injection every three months for patients who are already stable on oral therapy, as maintenance rather than as a starting regimen.
At what stage can we diagnose opportunistic infections, and how do we diagnose them?▼
Opportunistic infections can be diagnosed at any stage; the WHO staging system, grade one through four, is built around exactly this, using the infection profile and CD4 level together. Oral thrush, for instance, usually appears at stage two, while reactive generalised lymphadenopathy sits at stage one. Sometimes the opportunistic infection is itself the first clue to an undiagnosed HIV infection, tuberculosis being the clearest example: finding it usually puts the patient at WHO stage three, and a very low viral load and CD4 count below 200 to 250 lets you further risk-stratify from there. Diagnosis runs on three legs: the clinical symptoms and signs, which organ is involved, and targeted sampling, such as testing sputum by GeneXpert for suspected pulmonary tuberculosis, or testing CSF, or serum cryptococcal antigen when CSF isn't accessible, for cryptococcal meningitis.
What are the early signs of HIV?▼
The early signs, known as acute HIV syndrome, look like a flu. Most patients who are symptomatic present with intermittent fever for two to three months, fatigue or weakness, weight loss, loss of appetite, cough, cold, sore throat, more frequent minor illnesses than usual, and loose motions or diarrhoea. This symptom complex over the first month or two is what we call acute HIV syndrome.
In This Series: Tuberculosis & HIV - An Insight
- 1.Tuberculosis and HIV
- 2.How HIV Is Diagnosed: Getting the Testing Window Right
- 3.Starting Antiretroviral Therapy: Building the Regimen Around the Patient
- 4.Pre-Exposure Prophylaxis for HIV: Who Qualifies and How Well It Works
- 5.Post-Exposure Prophylaxis: Acting Within 72 Hours of a Possible HIV Exposure
- 6.Tuberculosis and HIV Co-Infection: Why the Two Diseases Compound Each Other
- 7.Preventing Mother-to-Child Transmission of HIV
- 8.When HIV Therapy Appears to Fail: Telling Adherence Problems From Real Failure
- 9.Long-Acting HIV Therapy and the Path Toward a Cure